CD33 and Alzheimer disease: In contrast, GM-CSF (a CSFR1 activating ligand) [191, 192], TREM2 agonists (both small molecule and antibody-based approaches) [193], and a CD33/Siglec3 antagonists [194] (antibody) are being developed as immune activating approaches for AD.